IRONWOOD PHARMACEUTICALS, INC. Severance Costs
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Severance Costs of $2.40 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2018-05-04
- IRONWOOD PHARMACEUTICALS, INC. severance costs for the quarter ending 2018-03-31 was $2.40M.
- IRONWOOD PHARMACEUTICALS, INC. severance costs for the quarter ending 2014-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. severance costs for the quarter ending 2014-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. severance costs for the quarter ending 2014-06-30 was $34.00K.
- IRONWOOD PHARMACEUTICALS, INC. severance costs for fiscal 2014 was $4.33M.
| Period end | Severance Costs 3 month | Severance Costs 3 month as first filed | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $2.40M 10-Q · filed 2018-05-04 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $0.00 derived: sum of 2 quarters · filed 2015-02-18 | $34.00K derived: sum of 3 quarters · filed 2015-02-18 | $4.33M 10-K · filed 2015-02-18 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $34.00K derived: sum of 2 quarters · filed 2014-11-05 | $4.33M 10-Q · filed 2014-11-05 | ||
| 2014-06-30 | $34.00K derived: 10-Q 6 month − 10-K 3 month · filed 2014-08-05 | $4.33M 10-Q · filed 2014-08-05 | |||
| 2014-03-31 | $4.30M 10-K · filed 2016-02-19 | $4.33M 10-Q · filed 2014-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |